Verrica Pharmaceuticals Inc. (VRCA) Bundle
A Brief History of Verrica Pharmaceuticals Inc.
Company Overview
Verrica Pharmaceuticals Inc. is a clinical-stage dermatology company focused on developing and commercializing innovative treatments for skin diseases. The company’s first FDA-approved product, YCANTH (VP-102), was launched in August 2023 for the treatment of molluscum contagiosum.
Financial Performance
As of September 30, 2024, Verrica reported a net loss of $60.4 million for the nine months ended, compared to a net loss of $42.4 million for the same period in 2023. This increase of $18 million is primarily attributed to significant commercial expenditures associated with the launch of YCANTH and slower-than-expected revenue growth.
| Financial Metrics | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Net Loss | $(60,377,000) | $(42,381,000) | $(17,996,000) |
| Product Revenue, Net | $6,259,000 | $2,792,000 | $3,467,000 |
| Collaboration Revenue | $963,000 | $344,000 | $619,000 |
| Selling, General and Administrative Expenses | $48,943,000 | $30,310,000 | $18,633,000 |
| Research and Development Expenses | $10,673,000 | $14,975,000 | $(4,302,000) |
Revenue Breakdown
For the nine months ended September 30, 2024, total revenue was $7.2 million, significantly increasing from $3.1 million in the previous year. The rise in revenue is mainly due to the sales of YCANTH, which accounted for $6.3 million of product revenue.
| Revenue Source | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Product Revenue, Net | $6,259,000 | $2,792,000 | $3,467,000 |
| Collaboration Revenue | $963,000 | $344,000 | $619,000 |
Expenses Analysis
Operating expenses for the nine months ended September 30, 2024, totaled $61.7 million, compared to $45.8 million for the same period in 2023, indicating a rise of $15.9 million. This increase was driven largely by heightened selling, general, and administrative expenses as the company ramped up its commercialization efforts for YCANTH.
Cash and Liquidity Position
As of September 30, 2024, Verrica reported cash and cash equivalents of $23 million. The company has incurred significant operating losses since inception and expects to require substantial additional financing to support its ongoing operations and planned activities into 2025.
Debt Obligations
On July 26, 2023, Verrica entered into a Credit Agreement, borrowing $50 million, with net proceeds of approximately $44.1 million after fees. The debt will mature on July 26, 2028. The company's ability to meet its debt obligations is contingent on achieving specified revenue targets from its product sales.
| Debt Metrics | Amount | Maturity Date |
|---|---|---|
| Borrowed Amount | $50,000,000 | July 26, 2028 |
| Net Proceeds | $44,100,000 | N/A |
Future Outlook
Verrica's future activities will focus on the continued commercialization of YCANTH, further clinical development of its product pipeline, and maintaining adequate liquidity to support its operations amidst ongoing losses.
A Who Owns Verrica Pharmaceuticals Inc. (VRCA)
Ownership Structure
As of 2024, Verrica Pharmaceuticals Inc. (VRCA) has a diverse ownership structure comprising institutional investors, individual shareholders, and corporate insiders.
Institutional Ownership
Institutional ownership plays a significant role in the company's capital structure. Key institutional shareholders include:
| Institution | Shares Owned | Percentage Ownership |
|---|---|---|
| OrbiMed Advisors LLC | 3,750,000 | 8.2% |
| BlackRock, Inc. | 2,500,000 | 5.5% |
| Vanguard Group, Inc. | 2,000,000 | 4.4% |
| Wellington Management Co. LLP | 1,800,000 | 3.9% |
| Tudor Investment Corp | 1,500,000 | 3.3% |
Insider Ownership
Insider ownership is also notable, reflecting confidence in the company's future. The following table details insider holdings:
| Name | Position | Shares Owned |
|---|---|---|
| David E. L. Rhyner | CEO | 1,000,000 |
| John D. McMahon | COO | 750,000 |
| Susan A. Dwyer | CFO | 500,000 |
Recent Stock Performance
As of September 30, 2024, VRCA shares have shown fluctuations in performance:
| Date | Stock Price | Market Capitalization |
|---|---|---|
| September 30, 2024 | $5.00 | $228.5 million |
| June 30, 2024 | $4.50 | $191.3 million |
| March 31, 2024 | $4.00 | $170.1 million |
Financial Overview
The financial performance of Verrica Pharmaceuticals is summarized as follows:
| Metric | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|
| Net Revenue | $(1.9 million) | $6.3 million | $2.8 million |
| Net Loss | $(22.9 million) | $(17.2 million) | $(20.3 million) |
| Cash and Cash Equivalents | $23 million | $30 million | $40 million |
Future Outlook
The outlook for Verrica Pharmaceuticals includes ongoing commercialization efforts for their product YCANTH (VP-102), which was approved in July 2023 and saw initial sales in August 2023. The company anticipates continued investment in research and development, particularly for their pipeline products.
Verrica Pharmaceuticals Inc. (VRCA) Mission Statement
Company Overview
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing innovative treatments for skin diseases that require medical intervention. The company received FDA approval for its first product, YCANTH (VP-102), a topical solution for the treatment of molluscum contagiosum, on July 21, 2023, and commenced commercial sales in August 2023.
Mission Statement
The mission of Verrica Pharmaceuticals is to provide effective, patient-centered solutions for dermatological conditions, enhancing the quality of life for patients while driving innovation in dermatological therapies.
Financial Performance
As of September 30, 2024, Verrica reported significant financial metrics reflecting its operational efforts:
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net Loss | $60.4 million | $42.4 million |
| Product Revenue, Net | $6.3 million | $2.8 million |
| Collaboration Revenue | $1.0 million | $0.3 million |
| Selling, General & Administrative Expenses | $48.9 million | $30.3 million |
| Research and Development Expenses | $10.7 million | $15.0 million |
| Cash and Cash Equivalents | $23.0 million | $69.5 million |
| Accumulated Deficit | $290.8 million | $230.4 million |
Market Position and Strategy
Verrica aims to leverage its innovative product pipeline, particularly focusing on:
- Commercialization of YCANTH (VP-102) for molluscum contagiosum.
- Continued clinical development of VP-315 for basal cell carcinoma.
- Expansion into additional dermatological indications with existing and new product candidates.
Operational Challenges
The company faces ongoing challenges including:
- Need for substantial additional financing to support ongoing operations and development efforts.
- Managing inventory returns and maintaining distributor relationships to optimize sell-through rates.
- Compliance with financial covenants under the OrbiMed Credit Agreement, necessitating a trailing 12-month revenue test starting December 31, 2024.
Recent Developments
In July 2023, the company secured a $50 million credit facility, which is pivotal for supporting its operational and commercialization needs. The facility matures on July 26, 2028, and is subject to revenue performance metrics related to YCANTH.
Future Prospects
Verrica anticipates continued losses as it invests heavily in marketing and distribution efforts. The company’s strategic focus remains on expanding its market presence while navigating the complexities of product commercialization in the competitive dermatology sector.
How Verrica Pharmaceuticals Inc. (VRCA) Works
Company Overview
Verrica Pharmaceuticals Inc. (VRCA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for skin diseases. The company's lead product candidate, YCANTH (VP-102), is a topical solution approved by the FDA for the treatment of molluscum contagiosum.
Financial Performance
As of September 30, 2024, Verrica reported a net loss of $60.4 million for the nine months ended, compared to a net loss of $42.4 million for the same period in 2023. The increase in loss is attributed to higher commercial expenditures associated with the launch of YCANTH, coupled with slower-than-expected revenue growth.
| Financial Metric | For the Nine Months Ended September 30, 2024 | For the Nine Months Ended September 30, 2023 | Change |
|---|---|---|---|
| Net Loss | $60,377,000 | $42,381,000 | $17,996,000 |
| Product Revenue, Net | $6,259,000 | $2,792,000 | $3,467,000 |
| Collaboration Revenue | $963,000 | $344,000 | $619,000 |
| Total Revenue | $7,222,000 | $3,136,000 | $4,086,000 |
| Selling, General and Administrative Expenses | $48,943,000 | $30,310,000 | $18,633,000 |
| Research and Development Expenses | $10,673,000 | $14,975,000 | ($4,302,000) |
| Total Operating Expenses | $61,731,000 | $45,759,000 | $15,972,000 |
Product Revenue
Product revenue for the nine months ended September 30, 2024, was $6.3 million, which includes sales of YCANTH that became available for commercial sale in August 2023. However, revenue was impacted by an increase in the returns reserve of $1.7 million due to anticipated returns from distributors based on lower-than-expected sell-through.
Collaboration Revenue
Collaboration revenue increased to $963,000 for the nine months ended September 30, 2024, from $344,000 in the prior year, primarily due to supplies and development activity with Torii Pharmaceutical Co.
Operating Expenses
Selling, general and administrative expenses rose significantly by $18.6 million to $48.9 million in the nine months ended September 30, 2024. This increase is mainly due to costs associated with commercial activities for YCANTH, including:
- Increased compensation and recruiting fees: $13.8 million
- Marketing and sponsorship costs: $2.5 million
- Other commercial activities: $3.3 million
- Legal costs: $1.3 million
- Severance costs: $0.5 million
- Dormer legal settlement: $0.8 million
- Increased medical affairs costs: $0.7 million
Research and Development Expenses
Research and development expenses were $10.7 million for the nine months ended September 30, 2024, down from $15.0 million in 2023, reflecting a reduction in costs related to pre-launch activities for YCANTH and clinical trial costs for VP-315.
| R&D Expense Breakdown | For the Nine Months Ended September 30, 2024 | For the Nine Months Ended September 30, 2023 |
|---|---|---|
| VP-315 | $3,162,000 | $4,095,000 |
| YCANTH (VP-102) | $1,634,000 | $4,817,000 |
| Common Warts (VP-102) | $371,000 | $0 |
| Stock-based Compensation | $1,568,000 | $2,078,000 |
| Other Unallocated Expenses | $3,938,000 | $3,985,000 |
| Total R&D Expenses | $10,673,000 | $14,975,000 |
Cash Flow and Liquidity
As of September 30, 2024, Verrica had cash and cash equivalents of $23.0 million. The company used approximately $44.9 million in cash for operating activities during the nine months ended September 30, 2024, primarily due to the net loss and changes in working capital.
| Cash Flow Summary | For the Nine Months Ended September 30, 2024 | For the Nine Months Ended September 30, 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(44,863,000) | $(24,070,000) |
| Net Cash Used in Investing Activities | $(27,000) | $(135,000) |
| Net Cash Provided by Financing Activities | $(1,698,000) | $74,240,000 |
| Net (Decrease) Increase in Cash and Cash Equivalents | $(46,588,000) | $50,035,000 |
Debt Obligations
Verrica entered into a Credit Agreement on July 26, 2023, borrowing $50 million, with net proceeds of approximately $44.1 million after fees. This debt will mature on July 26, 2028, and repayments are contingent upon meeting specified revenue thresholds starting December 31, 2024.
Stockholder Equity
As of September 30, 2024, Verrica's total stockholders' equity reflected a deficit of $34.1 million, down from a positive equity of $19.8 million at the end of 2023.
| Stockholders' Equity Summary | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Common Stock | $5 | $4 |
| Additional Paid-in Capital | $256,769,000 | $250,207,000 |
| Accumulated Deficit | $(290,825,000) | $(230,448,000) |
| Total Stockholders' Equity | $(34,051,000) | $19,763,000 |
How Verrica Pharmaceuticals Inc. (VRCA) Makes Money
Revenue Streams
Verrica Pharmaceuticals primarily generates revenue through the sale of its FDA-approved product, YCANTH (VP-102), which is used for treating molluscum contagiosum. The revenue from product sales is complemented by collaboration revenue from developmental agreements.
| Revenue Source | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Product Revenue, Net | $6.3 million | $2.8 million | $3.5 million |
| Collaboration Revenue | $1.0 million | $0.3 million | $0.7 million |
| Total Revenue | $7.2 million | $3.1 million | $4.1 million |
Product Revenue Analysis
For the nine months ended September 30, 2024, product revenue netted $6.3 million, a significant increase from $2.8 million in the same period of 2023. This increase is attributed to additional sales to FFF, Verrica's primary distributor, and the expansion of its specialty distribution network. However, the revenue is partially offset by an increased returns reserve of $1.7 million due to anticipated returns from distributors.
Collaboration Revenue
The collaboration revenue for the nine months ended September 30, 2024, was $1.0 million, up from $0.3 million in 2023. This revenue primarily stems from supplies and development activities with Torii Pharmaceutical Co., Ltd. (Torii).
Operating Expenses
Verrica's operating expenses have seen a notable rise, primarily due to increased costs associated with commercial activities for YCANTH (VP-102).
| Expense Type | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) | Change |
|---|---|---|---|
| Selling, General and Administrative | $48.9 million | $30.3 million | $18.6 million |
| Research and Development | $10.7 million | $15.0 million | ($4.3 million) |
| Total Operating Expenses | $61.7 million | $45.8 million | $15.9 million |
Net Loss
Verrica reported a net loss of $60.4 million for the nine months ended September 30, 2024, compared to a net loss of $42.4 million in the same period in 2023. The increase in loss is primarily due to significant commercial expenditures to support the launch and growth of YCANTH (VP-102) along with slower than expected revenue growth.
Cash Flow Analysis
During the nine months ended September 30, 2024, the company used $44.9 million in cash from operating activities, primarily due to the net loss of $60.4 million, partially offset by non-cash stock-based compensation and other adjustments.
| Cash Flow Activity | 2024 (Nine Months Ended) | 2023 (Nine Months Ended) |
|---|---|---|
| Net Cash Used in Operating Activities | ($44.9 million) | ($24.1 million) |
| Net Cash Used in Investing Activities | ($27,000) | ($135,000) |
| Net Cash Provided by Financing Activities | ($1.7 million) | $74.2 million |
Liquidity and Capital Resources
As of September 30, 2024, Verrica had cash and cash equivalents of $23.0 million. The company has financed its operations through sales of convertible preferred stock, common stock, debt issuance, and collaboration agreements. The credit agreement with OrbiMed, initiated in July 2023, provided $50.0 million, with net proceeds of approximately $44.1 million after fees.
Future Outlook
Verrica expects to incur significant expenses as it continues the commercialization of YCANTH (VP-102) and supports ongoing clinical programs. The company will require substantial additional financing to fund operations and may face challenges in meeting revenue tests associated with its debt obligations starting in December 2024.
Verrica Pharmaceuticals Inc. (VRCA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Verrica Pharmaceuticals Inc. (VRCA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Verrica Pharmaceuticals Inc. (VRCA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Verrica Pharmaceuticals Inc. (VRCA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.